Defending Human Dignity
By Michael Cook,
BioEdge
| 09. 13. 2014
Untitled Document
English barrister and medical ethicist Charles Foster has penned defence of “human dignity” as the foundation of bioethics in the Cambridge Quarterly of Healthcare Ethics. He believes that it is more adequate than the reigning view that autonomy is its fundamental principle. In particular dignity does a far better job of explaining why body parts or patients in a vegetative state deserve respect.
Foster is well aware that the concept of dignity has weaknesses:
Dignity has a smug tendency to rest on its laurels. Its advocates have often responded to criticism of the use of dignity by philosophical name-calling—along the lines of “You don’t like dignity, and therefore you must be a Nazi/communist/utilitarian/shallow reductionist.” That’s not argument. It rightly produces derision from the dignity deniers. They tend to respond in kind, saying words to the effect of “You’re a credulous, theologically contaminated mystic.” And so it goes on. A lot of the literature on dignity is comprised of these sorts of exchanges. It is not amusing for long, and not productive at all.
However, autonomy is “hardly...
Related Articles
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Siddhi Mahatole and Mariam E. Sunny, Reuters | 06.13.2025
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' (REGN.O), opens new tab offer for the DNA-testing company in a bankruptcy auction.
Last month, Regeneron agreed to...